BRÈVE

sur GUERBET (EPA:GBT)

Important Changes to the Guerbet Board of Directors

On March 20, 2024, Guerbet, a globally recognized player in the contrast media and medical imaging solutions industry, formalized the appointment of Hugues Lecat as censor within its Board of Directors, with immediate effect. This decision foreshadows his potential appointment as director and then President of the company, subject to approval at the next General Meeting.

The arrival of Hugues Lecat is welcomed with enthusiasm by the members of the board and Eric Guerbet, who highlight his significant experience in the pharmaceutical sector and his strategic vision as assets for the future development of the group. Hugues Lecat, whose career has notably evolved at Medtronic France, Aventis Pharma France and Sanofi-Aventis OTC, is ready to support Managing Director David Hale to continue to position Guerbet as a leader in the field of diagnostic and interventional imaging.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de GUERBET